ストックスクリーナーアプリを入手
64.17
730.14%
56.44
プレマーケット:
50.60
-13.57
-21.15%
Mink Therapeutics Inc (INKT) 最新ニュース
MiNK Therapeutics, Inc.'s (NASDAQ:INKT) biggest owners are public companies who got richer after stock soared 787% last week - simplywall.st
MiNK Therapeutics: Leading the Allogeneic Cell Therapy Revolution with AgenT-797's Durable Solid Tumor Responses - AInvest
MiNK Therapeutics: AgenT-797 Solidifies Itself As iNKT Cell Therapy With Latest CR Data - Seeking Alpha
Best Medical Stocks To Keep An Eye On – July 11th - Defense World
MiNK Therapeutics' iNKT Cell Therapy: A Breakthrough in Solid Tumors and a Catalyst for Stock Upside - AInvest
Mink Therapeutics shares fall 19.28% in after-hours following publication of case study in Nature's Oncogene. - AInvest
Volume Stonkers | MiNK Therapeutics skyrocketed 730.14%, Significant Advancements in Cancer Treatment Research - AInvest
INKT Stock Quote Price and Forecast - CNN
Crude Oil Rises Sharply; Milestone Pharmaceuticals Shares Plunge - Benzinga
Why Is Nano-Cap MiNK Therapeutics Stock Gaining Over 400% On Friday? - Benzinga
MiNK Therapeutics soars over 500% after cancer therapy shows complete remission - TradingView
MiNK Therapeutics Says Testicular Cancer Patient Achieves Remission After INKT Cell Therapy - MarketScreener
MiNK Therapeutics Stock Soars On Patient Receiving Full Remission In Testicular Cancer With Investigational Cell Therapy - Stocktwits
MiNK Therapeutics Soars on Cancer Breakthrough: What’s Driving the INKT Surge? - RagingBull
MiNK Therapeutics stock soars after cancer remission breakthrough - Investing.com
MiNK Therapeutics Publishes Landmark Case of Complete Remission in Metastatic Testicular Cancer Following Treatment with AgenT-797 - Nasdaq
MiNK Therapeutics Announces Publication of Complete - GlobeNewswire
Complete Remission Achieved in Treatment-Resistant Testicular Cancer with iNKT Cell Therapy | INKT Stock News - Stock Titan
MiNK Therapeutics (NASDAQ:INKT) Trading 0.6% Higher – Should You Buy? - Defense World
Where are the Opportunities in (INKT) - news.stocktradersdaily.com
Kalkine: MiNK Therapeutics Sees Gains Amid Positive Earnings Per Share Momentum - Kalkine Media
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting - Eagle-Tribune
MiNK Therapeutics Annual Meeting: How Shareholders Can Join Virtually on June 18 - Stock Titan
MiNK Therapeutics (NASDAQ:INKT) Stock Price Up 0.1% – Here’s Why - Defense World
MiNK Therapeutics receives NIH grant for GvHD therapy - Investing.com India
MiNK Therapeutics, Inc. Awards Prestigious Niaid Grant to Advance Allo-Inkt Cell Therapy for Prevention of Gvhd in Stem Cell Transplant Patients - MarketScreener
INKT Secures Grant for GvHD Cell Therapy Development | INKT Stoc - GuruFocus
MiNK Therapeutics Receives NIAID Grant to Advance Allo-iNKT Cell Therapy for Graft-Versus-Host Disease Treatment - Nasdaq
MiNK Therapeutics Awarded Prestigious NIAID Grant to - GlobeNewswire
NIH Backs Revolutionary Cell Therapy: MiNK's Solution Could Prevent Deadly Transplant Complications - Stock Titan
(INKT) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Amer Sports: The New ONON and DECK of Consumer Discretionary? - The Globe and Mail
MiNK Therapeutics outlines near-term partnering proposals and reduced cash burn as company advances iNKT programs - MSN
HC Wainwright Cuts Earnings Estimates for MiNK Therapeutics - Defense World
MiNK Therapeutics, Inc. (NASDAQ:INKT) Q1 2025 Earnings Call Transcript - Insider Monkey
MiNK Therapeutics Reports Q1 2025 Progress and Financials - TipRanks
Mink Therapeutics’ Earnings Call Highlights Progress and Optimism - TipRanks
Transcript : MiNK Therapeutics, Inc., Q1 2025 Earnings Call, May 15, 2025 - marketscreener.com
MiNK Therapeutics (INKT) Advances in Immune Response Innovation - GuruFocus
MiNK Therapeutics (INKT) Advances in Immune Response Innovation | INKT Stock News - GuruFocus
MiNK Therapeutics Reports Clinical Advancements and Financial Update for Q1 2025, with Focus on iNKT Cell Therapies - Nasdaq
Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress - GlobeNewswire
MiNK Therapeutics (INKT) Projected to Post Earnings on Tuesday - Defense World
Refractory Multiple Myeloma Pipeline Appears Robust With 75+ - openPR.com
How to Take Advantage of moves in (INKT) - news.stocktradersdaily.com
MiNK Therapeutics to Announce Q1 2025 Financial Results and Host Conference Call on May 15th - Nasdaq
MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report - GlobeNewswire
Geode Capital Management LLC Lowers Stock Position in MiNK Therapeutics, Inc. (NASDAQ:INKT) - Defense World
INKTMink Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Learn to Evaluate (INKT) using the Charts - news.stocktradersdaily.com
Comparing Atyr PHARMA (NASDAQ:ATYR) and MiNK Therapeutics (NASDAQ:INKT) - Defense World
ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia - Business Wire
LIfT BioSciences appoints new CSO - Bdaily
LIfT BioSciences Appoints Mark A. Exley as Chief Scientific Officer - EIN News
ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch - Business Wire
(INKT) Trading Report - news.stocktradersdaily.com
Reviewing MiNK Therapeutics (NASDAQ:INKT) & Creative Medical Technology (NASDAQ:CELZ) - The AM Reporter
HC Wainwright Issues Negative Forecast for INKT Earnings - Defense World
What is William Blair’s Forecast for INKT Q1 Earnings? - Defense World
2.10%
1.57%
大文字化:
|
ボリューム (24 時間):